Elkammash Amr, Farahat Rasha M, Al Sattouf Aya, Lenaerts Julius, Maung Khin Yadanar, Khatri Aayesha
Cardiology, Royal Papworth Hospital NHS Foundation Trust, Cambridge, GBR.
Medicine, West Suffolk NHS Foundation Trust, Suffolk, GBR.
Cureus. 2022 Oct 16;14(10):e30348. doi: 10.7759/cureus.30348. eCollection 2022 Oct.
Iron is vital for multiple biological processes in the human body. Heart failure (HF) patients are at a high risk of becoming iron deficient. Iron deficiency is a marker of severe HF and an ominous sign of poor outcomes. Iron deficiency can be absolute (low iron stores) or functional (improper functioning in the metabolic processes). The European Society of Cardiology recommends routine screening of iron stores in HF patients using ferritin and transferrin saturation. It advises iron replacement in deficient patients irrespective of the presence of anemia. Iron replacement improved HF symptoms, exercise capacity, and quality of life in deficient patients. It alleviates their disordered breathing during sleep. Therefore, the treatment of iron deficiency is an important target in managing HF. Oral iron is not effective in repleting iron stores in HF patients. Intravenous iron is an effective way to replenish iron stores in this cohort.
铁对人体的多种生物过程至关重要。心力衰竭(HF)患者缺铁风险很高。缺铁是严重HF的一个标志,也是预后不良的不祥征兆。缺铁可以是绝对性的(铁储备低)或功能性的(代谢过程中功能异常)。欧洲心脏病学会建议使用铁蛋白和转铁蛋白饱和度对HF患者进行铁储备的常规筛查。它建议对缺铁患者进行铁补充,无论是否存在贫血。铁补充改善了缺铁患者的HF症状、运动能力和生活质量。它减轻了他们睡眠期间的呼吸紊乱。因此,缺铁的治疗是管理HF的一个重要目标。口服铁对补充HF患者的铁储备无效。静脉注射铁是补充该队列中铁储备的有效方法。